All In Biotech

Drug Trial Radar · NCT03490123

Evaluation of an Intensive 3-round MDA Strategy Towards Yaws Eradication

Defining the Best Distribution Strategy of Azithromycin for Yaws Eradication (The Yaws 3 Trial)

Last checked: Nov 19, 2026Latest source record: Jun 23, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 56,000 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

56,000

Actual

Start

Apr 16, 2018

Primary completion

Apr 1, 2020

Study completion Apr 1, 2020

Sponsor

Lead sponsor
Lihir Medical CentreAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Barcelona Institute for Global Health; National Department of Health, Papua New Guinea; World Health Organization; University of Masarykova; Harvard School of Public Health (HSPH)
First posted
Apr 6, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 6 months
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The current principle of yaws eradication (the Morges strategy) is based on single round mass drug administration (MDA) of azithromycin (AZI) called total community treatment (TCT) followed by targeted treatment of active cases every 6 months to detect and treat cases and contacts called total targeted treatment (TTT). Studies done in Papua New Guinea (PNG) show that 1 round of MDA will probably not suffice to stop transmission of infection. It may be preferable to conduct 3 rounds of MDA prior to the switch to TTT because of high coverage requirements to achieve elimination, particularly of latent cases. The investigators plan to determine whether 3 rounds of MDA are more effective for reaching yaws elimination. This research is needed to guide national programmatic implementation and needs to be done as soon as possible to scale up the program in the country. The aim of this proposal is to ascertain the number of rounds of MDA with AZI to be included in an improved strategy towards yaws eradication. The study will be implemented in 38 wards of New Ireland Province (NIP). The investigators will compare two different distribution strategies of MDA: (A) strategy with 3 biannual rounds of MDA and (B) a single mass treatment round of MDA followed by targeted treatment of cases and contacts. The investigators will also monitor the risk of appearance of antimicrobial resistance in Treponema pertenue.

Conditions

  • Yaws

Interventions

  • R1-Total community treatment with azithromycinDrug

    At month 0, all study participants (regardless of their yaws status) will receive 30 mg/Kg (maximum 2 g) of azithromycin orally under direct observation. Benzathine benzylpenicillin will be reserved as a backup for patients who cannot be treated with AZI, and who are not allergic to penicillin.

  • R2-Total community treatment with azithromycinDrug

    At month 6, all study participants (regardless of their yaws status) will receive 30 mg/Kg (maximum 2 g) of azithromycin orally under direct observation. Benzathine benzylpenicillin will be reserved as a backup for patients who cannot be treated with AZI, and who are not allergic to penicillin.

  • R3-Total community treatment with azithromycinDrug

    At month 12, all study participants (regardless of their yaws status) will receive 30 mg/Kg (maximum 2 g) of azithromycin orally under direct observation. Benzathine benzylpenicillin will be reserved as a backup for patients who cannot be treated with AZI, and who are not allergic to penicillin.

  • R2-Total targeted treatment with azithromycinDrug

    At 6 months, study participants will be screened for active yaws. Participants with yaws and their contacts will receive 30 mg/Kg (maximum 2 g) of azithromycin orally under direct observation. Benzathine benzylpenicillin will be reserved as a backup for patients who cannot be treated with AZI, and who are not allergic to penicillin.

  • R3-Total targeted treatment with azithromycinDrug

    At 12 months, study participants will be screened for active yaws. Participants with yaws and their contacts will receive 30 mg/Kg (maximum 2 g) of azithromycin orally under direct observation. Benzathine benzylpenicillin will be reserved as a backup for patients who cannot be treated with AZI, and who are not allergic to penicillin.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Prevalence of active and of latent yaws at 18 monthsTime frame: 18 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Namatanai Rural Hospital

    Kavieng, New Ireland Province, Papua New Guinea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.